Please login to the form below

Not currently logged in

Hugh Cole leaves Shire for Ariad

Appointed chief business officer at company behind Iclusig

Ariad, Hugh ColeHugh Cole has left his role at Shire to join Ariad Pharmaceuticals as chief business officer.

In this role Cole will report to CEO Dr Harvey Berger and will be responsible for the company's global business and corporate development, licensing and strategic planning.

Cole spent seven years at Shire, most recently as senior VP, strategic planning and programme management. Prior to this he was a global franchise lead and VP, business development.

At Shire he gained experience in the orphan drugs market, which will benefit Ariad as it prepares to grow its portfolio of drugs targeted to treat rare, difficult-to-treat forms of cancer.

This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

The appointment of a chief business officer is a sign of confidence from Ariad, which last year faced safety concerns about Iclusig, but has since seen the drug backed by both the EMA and the FDA, although with new safety recommendations.

CEO Berger said: “[Cole] will be integral in seeking business and corporate development opportunities for Ariad, including a commercial partnership for Iclusig in Japan, as well as helping to further maximise our oncology pipeline.”

8th April 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?